宫颈癌放化疗患者贫血及其治疗现状的调查研究

文章编号] 1673-9701（2019）16-0131-05

[Abstract] Objective To explore the risk factors of radiotherapy and chemotherapy and anemia in patients with cervical cancer， and to provide more objective evidence for the treatment of cervical cancer. Methods The clinical data of cervical cancer patients who received radiotherapy and chemotherapy（combined radiochemotherapy or chemotherapy alone or radiotherapy alone） from July 2017 to December 2017 were retrospectively analyzed. 272 patients with cervical cancer were included. The data of anemia， pathology， tumor treatment and anemia-related treatment were analyzed， and the influencing factors of tumor-related anemia were discussed. Results Of the 272 cervical cancer patients， 231 had anemia， including 146 cases of mild anemia， 83 cases of moderate， and 2 cases of severe. The incidence of anemia was highest in cervical cancer patients in stage Ⅳ， and there was no significant difference in the incidence of anemia in patients with stage Ⅰ， Ⅱ， and Ⅲ cervical cancer. Among different pathological types， the incidence of anemia in adenocarcinoma， adenosquamous carcinoma and squamous cell carcinoma was 91.7%， 85.7% and 84.4%， respectively. Of the 231 anemia patients， 81.4% were not effectively treated. The most commonly used treatments for tumor-associated anemia were iron therapy， EPO therapy， blood transfusion therapy， and proprietary Chinese medicine. The application rates were 15.2%， 9.9%， 3.5%， and 0.9%. The treatment rate of patients with moderate to severe anemia was higher than that of patients with mild anemia[43.5%（37/85） vs 4.1%（6/146）， P=0.000）. Conclusion The incidence of anemia in patients with cervical cancer undergoing radiotherapy and chemotherapy is high， only 18.6% of these patients have received treatment， and more than 4/5 of patients have not been effectively treated. Cervical cancer-related anemia treatment is worthy of the attention of doctors.